Dimensional Fund Advisors
LYEL icon

Dimensional Fund Advisors’s Lyell Immunopharma LYEL Stock Holding History

Dimensional Fund Advisors’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$957K Buy
68,315
+20,427
+43% +$370K ﹤0.01% 2872
2026
Q1 		$959K Buy
+47,888
New +$1.12M ﹤0.01% 2850
2025
Q2 		– Sell
-673
Closed -$7.24K – 3309
2025
Q1 		$7.24K Hold
673
– – ﹤0.01% 3318
2024
Q4 		$8.62K Sell
673
-157
-19% -$3.11K ﹤0.01% 3337
2024
Q3 		$22.9K Sell
830
-1,175
-59% -$34.5K ﹤0.01% 3329
2024
Q2 		$58.1K Buy
2,005
+1,332
+198% +$63.4K ﹤0.01% 3299
2024
Q1 		$30K Hold
673
– – ﹤0.01% 3353
2023
Q4 		$26.1K Hold
673
– – ﹤0.01% 3381
2023
Q3 		$19.8K Hold
673
– – ﹤0.01% 3443
2023
Q2 		$42.8K Sell
673
-1,464
-69% -$81K ﹤0.01% 3417
2023
Q1 		$101K Buy
+2,137
New +$114K ﹤0.01% 3297
2022
Q3 		$874K Buy
+5,964
New +$808K ﹤0.01% 2919

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Dimensional Fund Advisors's LYEL Position: Q2 2026 in Review

Dimensional Fund Advisors increased its Lyell Immunopharma (LYEL) stake by 43% in Q2 2026, buying an estimated $370K and bringing the position to 68,315 shares worth $957K. The position accounts for ﹤0.01% of the portfolio, ranked #2872.

Dimensional Fund Advisors first reported a position in LYEL in Q3 2022 and has held it in 12 quarters since. The position peaked at $959K in Q1 2026. 87 funds tracked by Wall St. Rank hold LYEL as of Q2 2026.

  • Dimensional Fund Advisors held 68,315 shares of Lyell Immunopharma worth $957K as of Q2 2026.
  • Dimensional Fund Advisors bought 20,427 Lyell Immunopharma shares in Q2 2026, an estimated $370K.
  • Lyell Immunopharma made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q2 2026, its #2872 holding.
  • Dimensional Fund Advisors first reported a position in Lyell Immunopharma in Q3 2022 and has held it in 12 quarters since.
  • Dimensional Fund Advisors's Lyell Immunopharma position peaked at $959K in Q1 2026.
  • 87 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2026.

Based on Dimensional Fund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.